Experimental Weight-Loss Drug Reduces Knee Osteoarthritis Pain in Phase III Trials
Source Summary
Two Phase III clinical trials led by Northwestern University involving over 1,000 participants found that retatrutide, an experimental weight-loss injectable drug, helped ease painful knee osteoarthritis in overweight and obese patients. Participants taking the highest dose lost approximately one-quarter of their body weight on average, which improved their ability to perform daily activities such as walking, climbing stairs, and standing.
Why it matters
The trials demonstrate that weight loss achieved through retatrutide can provide meaningful clinical relief from knee osteoarthritis symptoms, potentially offering a new treatment option for patients with obesity-related joint pain.
